Boost for GVHD treatment

The US FDA has given orphan status to Glassia from Israel’s Kamada, to treat Graft-versus-host-disease (GVHD).  Preliminary studies indicate that Glassia may be able to treat and reduce the severity of GVHD, a key life-threatening complication of stem cell transplantation from another person.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *